JOSHUA DAWSON HOUSE, DUBLIN 2, L2
Evaluation of a Synthetic Formulation of Mebufotenin for Treatment-Resistant Depression in a Phase 2b Clinical Trial
Enters At-the-Market Equity Offering Sales Agreement
.3 Research Reports First Quarter 2026 Financial Results and Provides Business Update
Will Attend the American Psychiatric Association Annual Meeting
.4
Announces Pricing of $117.5 Million Underwritten Offering
March 2026 Ultra-Rapid, Durable Remission in TRD with Minimal Clinic Burden
Will Participate in a Panel Discussion During the RBC Capital Markets Psychedelics Symposium: A Trip Into the Future of Mental Health
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
No filings found
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership
Correspondence